An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model

Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (RCC). However, despite the combination of two ICIs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueki, Hideto, Kitagawa, Koichi, Kato, Mako, Yanase, Shihoko, Okamura, Yasuyoshi, Bando, Yukari, Hara, Takuto, Terakawa, Tomoaki, Furukawa, Junya, Nakano, Yuzo, Fujisawa, Masato, Shirakawa, Toshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281997/
https://www.ncbi.nlm.nih.gov/pubmed/37340017
http://dx.doi.org/10.1038/s41598-023-37234-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281997/
https://www.ncbi.nlm.nih.gov/pubmed/37340017
http://dx.doi.org/10.1038/s41598-023-37234-6

Ejemplares similares